Geographic Area
On the heels of FDA nod for cancer drug, Sun Pharma buys Checkpoint Therapeutics for up to $416M
UNLOXCYT, Checkpoint Therapeutics, Squamous cell carcinoma of skin, United States Food and Drug Administration, Sun Pharma
US judge blocks Trump administration from cutting NIH grants amid ongoing litigation
United States National Institutes of Health, Judge, injunction, implementing
In an unusual move, Lilly seeks pitches from US states for slice of $27B buildout
Eli Lilly, Investments, United States, Lilly ‘s
DOGE terminates leases for 30 FDA sites across 23 states
DOGE, United States Food and Drug Administration, Site, United States Food and Drug Administration, Clinical action, Government, leases
Australia Rejects Eisai’s Alzheimer’s Drug Leqembi
Leqembi, Eisai, Alzheimer’s disease, Australia, TGA, drug rejection
Australia steadfast on rejection of Eisai, Biogen’s Alzheimer’s therapy Leqembi
Lecanemab, Eisai, Leqembi, Alzheimer ‘s disease, Decision, Presenile dementia, Australia
Eikon pulls in $351M as lead drug begins Phase III journey
Eikon Therapeutics Secures $351M Funding for Cancer Drug Development Eikon Therapeutics raised $351 million in a Series D funding round124 Total funding raised since 2019 launch now exceeds $1.1 billion1 Lead drug EIK1001 has entered Phase III trials for advanced melanoma14 Clinical studies ongoing in 28 countries across 5 continents14 ## Pipeline Highlights: EIK1001: TLR7/8 […]
Merck & Co. predicts Keytruda will undergo IRA price cuts before patent cliff
Merck, Keytruda, Prices, IRA, Sales – occupational activity, patent cliff, Impact food supplement, U.S., Keytruda
5 Market Access Mistakes That Can Derail Your EU Orphan Drug Launch
EU, Market, Access, Failed, NR4A2 gene
Legal Battle Erupts as Deerfield Accuses Alcon of Obstructing Aurion Biotech’s IPO Plans
Aurion Biotech, Alcon Research, Deerfield Management , Initial Public Offering (IPO), Legal dispute, Biotech industry, Corporate governance, Shareholder rights, Delaware Court of Chancery